Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$5.7 million.

  • Benitec Biopharma's Net Cash Flow fell 11544.67% to -$5.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $46.9 million, marking a year-over-year decrease of 326.13%. This contributed to the annual value of $46.9 million for FY2025, which is 326.13% down from last year.
  • According to the latest figures from Q2 2025, Benitec Biopharma's Net Cash Flow is -$5.7 million, which was down 11544.67% from $25.3 million recorded in Q1 2025.
  • Benitec Biopharma's Net Cash Flow's 5-year high stood at $36.8 million during Q2 2024, with a 5-year trough of -$6.3 million in Q1 2024.
  • Over the past 5 years, Benitec Biopharma's median Net Cash Flow value was -$3.4 million (recorded in 2021), while the average stood at $4.6 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 16342.32% in 2022, then soared by 99811.97% in 2024.
  • Benitec Biopharma's Net Cash Flow (Quarter) stood at -$3.3 million in 2021, then crashed by 76.25% to -$5.9 million in 2022, then grew by 9.43% to -$5.3 million in 2023, then soared by 291.76% to $10.2 million in 2024, then tumbled by 155.87% to -$5.7 million in 2025.
  • Its Net Cash Flow stands at -$5.7 million for Q2 2025, versus $25.3 million for Q1 2025 and $10.2 million for Q4 2024.